SAN FRANCISCO (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and Cynvenio Biosystems, Inc., a cancer diagnostics company, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by Cynvenio. The combined molecular testing and medical informatics solution will enable a more personalized approach to disease management by physicians who incorporate the results of molecular diagnostic testing into patient treatment planning.

Under the current agreement, multiple CollabRx products, including the Genetic Variant Annotation (GVA) Service(TM) will be paired with tumor mutation profiling conducted by Cynvenio. Reports developed using the GVA Service will be offered with the Cynvenio ClearID Breast Cancer blood test, for monitoring breast cancer survivors at high risk of recurrence. ClearID identifies circulating tumor cells carrying cancer-associated mutations with next generation sequencing. Cynvenio will combine the results of these tests with clinically actionable and dynamically updated data provided by the CollabRx GVA Service. The GVA database includes information on the clinical impact of specific genetic profiles and associated therapeutic strategies such as drugs and investigational therapies being tested in clinical trials. This knowledge is further contextualized in collaboration with CollabRx's large and growing network of over 75 leading clinical practitioners in the U.S. and Europe.

"A contextualized interpretation of sequencing results is required to make the results of genomic tests actionable for physicians providing highly personalized cancer treatments to their patients," said André[<00E9>][<00E9>] de Fusco, CEO of Cynvenio. "CollabRx has developed a scalable process and software platform to provide key elements of the reporting solution that Cynvenio provides to aid physicians in the clinical interpretation of tumor-specific molecular profiles. We are pleased to be able to include GVA with our molecular testing services."
"Cynvenio has introduced an innovative, blood test to help monitor for disease in breast cancer survivors at high risk for recurrence," said Thomas Mika, Chairman, President & CEO of CollabRx. "Their approach of combining the detection of circulating tumor cells with genomic analysis is important for the early detection of cancer, choice of therapy, and ultimately to achieve the best possible clinical outcomes for breast cancer patients. We chose to extend CollabRx expertise and services to 'liquid biopsy' for the first time with Cynvenio because they are at the forefront of the sector with a strong focus on advancing personalized medicine in cancer."

More HCB News